Patents
Our European, UK and German experts advise on the creation, exploitation and enforcement of IP rights across a wide range of sectors. They provide creative IP solutions and outstanding client service.
MORE
The Boult trade mark team has market-leading experience before the UK Intellectual Property Office, the European Union Intellectual Property Office (EUIPO), the World Intellectual Property Organisation (WIPO), and foreign registries, in overcoming objections, successfully prosecuting and defending oppositions and appeals, and in revocation and invalidity work. The team has years of experience acting before the German Patent and Trade Mark Office (DPMA), the German courts, the Spanish Patent and Trademark Office (SPTO), the Spanish Civil and Commercial Courts, and similarly at the General Court, CJEU. We help in securing registrations for our clients, sometimes for difficult or unusual marks.
Given that it is better not to have a costly dispute when it can be avoided, a large part of the team’s work is in the field of dispute avoidance and dispute resolution. We are highly skilled and experienced negotiators in trade mark law and trade mark registration, understanding the likely endgame and using that knowledge to leverage good outcomes for our clients. We have particular expertise in the creation and management of large portfolios, searching and watching, domain name recovery, and trading standards and customs work. We understand that a business strategy may include expanding into new territories overseas and a client may require a local representative. In addition to our offices in the UK, Germany and Spain, we have developed strong relationships with local IP firms throughout the world.
The team supports horticultural and biopharma clients, has significant experience in UK plant breeders' rights, can assist clients in obtaining rights across Europe and offers advice on infringement risks associated with rights held by third parties.
MOREIn G1/25, the EPO President confirms that amended claims must be matched by description amendments under Article 84 EPC, in both examination and opposition.
UK IPO to raise patent, trade mark and design fees by 25% from 1 April 2026. Early renewals in some cases can secure current rates. Portfolio planning now essential.
Overview of EMA-defined biosimilars, EU IP protections and limits including Bolar exemption, SPC manufacturing waiver, skinny labelling and loss of exclusivity strategies.
The UK Supreme Court has reshaped software patent assessment, moving away from Aerotel toward greater EPO harmonisation and confirming that an ANN is a “program for a computer.”